This content is in French.
The vaccine that challenges the standards
28 avril 2025
#Malaria #Vaccination #GA2 #AttenuatedParasites
Despite decades of efforts, preventive campaigns, mass distribution of bed nets, and antimalarial treatments, malaria continues to claim more than 600,000 lives each year. Children under five years old represent the majority of these deaths, particularly in high-transmission areas of sub-Saharan Africa. This situation underscores the limitations of current tools against a disease that adapts, persists, and resists.
Despite decades of efforts, preventive campaigns, mass distribution of bed nets, and antimalarial treatments, malaria continues to claim more than 600,000 lives each year. Children under five years old represent the majority of these deaths, particularly in high-transmission areas of sub-Saharan Africa. This situation underscores the limitations of current tools against a disease that adapts, persists, and resists.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Roozen, G. V. T., et al. (2025). Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. Nature medicine, 31(1), 218–222.
View the source
